Phacilitate Cell & Gene Therapy World
03 JANUARY 2017
One of the most pressing issues facing the cell and advanced therapy industry today is the challenge of developing commercial therapies at an appropriate go-to-market price.
During the Phacilitate Cell & Gene Therapy World Conference in Miami this January, senior members of Invetech’s Cell Therapy Group, Richard Grant and Brian Hanrahan, will be joined by industry leaders from Novartis, bluebird bio and Celyad, to explore this challenge and the opportunities to overcome it through automation.
Plenary Presentation: In Pursuit of the $1,000 Therapy
January 18, 2017 from 10:25 to 10:45 am
Speaker: Richard Grant (Invetech)
The $1,000 genome challenge saw the price of sequencing a genome tumble from $100M (US) in 2002 to the target range in 2016. Should the cell therapy industry set a similarly audacious target? And, if so, what can we do now to get the ball rolling?
Invetech’s Annual Breakfast Briefing: Meeting the Cell Therapy Cost Challenge with Automation
January 19, 2017 from 7:30 to 9:00 am
Chair: Brian Hanrahan (Invetech)
Panelists: Rodney Rietze (Novartis Pharmaceuticals), Peter Olagunju (bluebird bio) and Dieter Hauwaerts (Celyad)
The next grand challenge for the cell and advanced therapies industry is to dramatically lower the cost of manufacturing a (cell) therapy. Hear how industry leaders from Novartis, bluebird bio and Celyad are addressing this challenge as they discuss and debate methods of using automation to achieve a step-change reduction in the cost of therapies and share their visions for a competitive future.